RCM
CORT icon

Rotella Capital Management’s Corcept Therapeutics CORT Stock Holding History

Rotella Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-27,501
Closed -$137K – 63
2015
Q4 		$137K Buy
27,501
+2,115
+8% +$9.54K 0.12% 270
2015
Q3 		$95K Buy
25,386
+8,700
+52% +$44.2K 0.03% 435
2015
Q2 		$100K Buy
+16,686
New +$102K 0.08% 278

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Rotella Capital Management's CORT Position: Q1 2016 in Review

Rotella Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2016, closing a stake of 27,501 shares — an estimated $137K sold.

Rotella Capital Management first reported a position in CORT in Q2 2015 and held it in 3 quarters. The position peaked at $137K in Q4 2015. 96 funds tracked by Wall St. Rank hold CORT as of Q1 2016.

  • Rotella Capital Management reported no remaining Corcept Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 27,501 Corcept Therapeutics shares in Q1 2016, an estimated $137K.
  • Rotella Capital Management first reported a position in Corcept Therapeutics in Q2 2015 and held it in 3 quarters.
  • Rotella Capital Management's Corcept Therapeutics position peaked at $137K in Q4 2015.
  • 96 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.